In Search of Better Tools and Capabilities "We need to do more with less." This is a common theme we hear in our conversations and follow up with Researchers in early phase drug discovery. To us this translates into better identification and more intense screening of potential therapeutic compounds and targets. Failure is success if it is determined before animal testing. The foundation being potent, pure and easy to culture primary cells. Then building on the platform with the required media/growth factors, markers, transfection reagents and apoptosis detection kits.

1. Tools and Capabilities
Focus on cell based assays
and gene expression analysis
for early phase Drug Discovery
3/5/2011-Version 4

2. Focus:
 Provide researchers a subset of tools and methods to enable
successful outcomes in early phase drug discovery. Failure is
success when determined early.
Value (simplified):
 Physiologically relevant primary human (STEMEZ™), rat and
mouse cells
 Better in vitro screening of targets and molecules
 Reduced animal model use
 Shorten development timeline
 Lower downstream costs
Images: STEMEZ™ hNP1™ can be
differentiated into various neuronal
subtypes under defined conditions.
DAPI
GFAP Antibody
• > 80% Tuj1+
• > 60% MAP2+
3/5/2011

3. Why Neuromics?
Standing out in a crowded room
 We have a experience serving many large Pharmas, Biotechs,
Academic and Government Labs.
 Customer success focused
 Expert technical support
 Detailed protocols and methods
 Quick replacements and reorders
 Large expert resource network
 Published expert input
 Customer feedback and data sharing through
social media outlets and blogs
3/5/2011

4. Stable, Potent and Cost Effective Cells
Growth Derived and
manufactured
Factors/Markers neural cells from Applications include:
human
embryonic stem
Media/3-D cell line H9 •Proliferation and
Gels/ECMS (WA09). neurogenesis
•Neuronal differentiation
•Neurite outgrowth
Gene Expression •Cell migration
Analysis •Neurotoxicity screening
•Cell based compound
Apoptosis screening
Detection •G-protein coupled receptors
•Ion channels
Cell Migration •Stem cell transplantation
Assays
Testimonial: got 10 million cells total after extraction from the tissue. At Day 4 they all developed long axons.
Thank you so much for the replacement." Dr. Lidia Gardner, University of Tennessee HSC..
3/5/2011

5. Assay kits, Qualified Media and Reagents-Sample
Images
Markers/Antibodies Growth Factors/Culture Media Gene Expression Analysis Apoptosis Detection
Imges: GFAP (Catalog#:
STEMEZTMhNP1 i-Fect knockdown of Delta Opioid Jurkat cells dually
aCH22102) Staining of of stained with Hoechst
Astrocytes in the Ventral Human Neural Receptor. Molecular Pain 2005,
horn. Courtesy of Dr. Qi-lin Progenitors treated 1:29 and Polycaspase
L. Cao, University of with hGDNF Assay Kit,
Louisville School of cultured in
Medicine. Rat spinal cord STEMEZ hNP1
homogenate WBs: NF-H,
NF-M,, NF-L,, NF66 and
Neural Progenitor
GFAP. Expansion Media
3/5/2011

6. Cell Based Assays-Examples
 STEMEZ hN2 Human Neural Discovery Kit
 Phenotyping
Neural phenotypes derived from N2 cell
lines. (A) Phase contrast image of
differentiated culture. (B) Network
including post-mitotic motoneurons
(HB9). (C) Cholinergic neuron. (D) Tuj-1
positive cells that are DAT-positive
(dopamine transporter; closed arrow)
and DAT-negative (open arrow). (E)
Gabaergic neurons, inset illustrates
GABA in axon, but not the dendrites
(arrow).
 Electrophysical and FLIPR Data Provided upon request
3/5/2011

7. Tools and Capabilities
Cell Based Assays-Examples
STEMEZ™ hNP1™ Human Neural Progenitor Kit is an efficient tool to quantitatively
detect both stimulators and inhibitors of cell migration when used with the OrisTM Cell
Migration Assay Kit (Platypus Technologies). Method development to date indicates that
the assay has the potential for adaptation as a homogenous HTS-suitable cell-based
assay.
3/5/2011

8. Cell Based Assays-Examples
 Primary Rat Neurons and Astrocytes
Transfection of functional HeV
glycoproteins and infection with HeV
pseudotyped virions.In order to establish
the feasibility of carrying out the proposed
experiments in primary neurons, we show
(figure ) that our assays are amenable to
use in primary neurons. In the experiment, Combined Hippocampus, Cortex, and Ventricular -E18
(Neuromics) were plated, and at 3 days were transfected with plasmids encoding HeV G/F as well
as YFP. On the following day, these cells were infected with HeV or VSV pseudotyped viruses
bearing RFP. In the figure, (A) the phase contrast photos show the differentiated neurons; (B)
upon excitation for RFP, the red fluorescence indicates neurons infected by HeV pseudotyped
virions; (C) upon excitation for YFP, and the green fluorescence shows the efficiency of
transfection in neurons. This experiment indicates that the proposed experiments can be carried
out in primary neurons, which are transfectable and infectable in our systems, and thus supports
all the proposed aims. Data Courtesy of Dr. Matteo Porotto, Weill Cornell Medical College. Larger
Image
3/5/2011

9. Cell Based Assays-Examples
 Primary Rat Neurons and Astrocytes
Data Courtesy of Evanna Gleason, Louisiana State University
3/5/2011

10.  Gene Expression Analysis
 It’s all about delivery!
 i-FectTM siRNA delivery kit : Success in delivering siRNA to
DOR, hTERT, The β3 subunit of the Na+,K+-ATPase,
rSNSR1, NTS1. NAV1.8, Survivin, TRL4, Flaviviruses and
more.
 Tools for delivering plasmids, proteins, antisense and
other small RNA and DNA molecule.
 Transfection Delivery: Customer Publications
3/5/2011

11. More Key Product Category Links:
 Antibodies-Markers
 Apoptosis Research Reagents -includes:
detection kits, antibodies and proteins
 Proteins Recombinant and natural proteins-
includes a wide selection of cell growth factors.
 Transfection Reagents-Gene Expression Analysis
 Cell Growth Media
3/5/2011

12.  Clear Understanding of where Neuromics could have
a positive impact.
 More intense in vitro screening of compounds and
targets.
 Better candidates for downstream processes.
 Propose solutions based on this understanding
 Follow up, tweak and improve
3/5/2011

13.  Pete Shuster
CEO and Owner
Direct Phone: 612-801-1007 www.neuromics.com
pshuster@neuromics.com www.neuromics.net
neuromics.blogspot.com
 Social Networking:
sirnatransfection.blogspot.com
3/5/2011